The most important thing is to be observant and highly attuned to your weight and appetite during the maintenance phase
"With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need." According to Eli Lilly, adults in the Phase 3 trials all lost weight with orforglipron and on the highest dose of 36 mg of orforglipron, the trial participants lost about 27 pounds over the course of 72 weeks or about 12% of their body weight, which is meaningful but not quite as high as some injectables
Here's what the evidence actually says about each assuming, generously, that the doses on the patch could even reach your bloodstream
Nathanson D, Erdogdu O, Pernow J, Zhang Q, Nystrom T
Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance
Cleveland Clinic describes GLP-1 agonists as a class of medications that mainly help manage blood sugar levels for people with T2D, but notes that due to the drugs satiety effect, they can often promote weight loss
